Literature DB >> 8221636

Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma.

F Cavallo1, F Di Pierro, M Giovarelli, A Gulino, A Vacca, A Stoppacciaro, M Forni, A Modesti, G Forni.   

Abstract

The potential of interleukin 2-gene-transfected tumor cells to prevent tumor growth and cure established tumors was evaluated using cells from a spontaneous, invasive, and metastasizing mouse mammary adenocarcinoma. Tumor cells engineered to secrete interleukin 2 initially trigger a local inflammatory reaction that leads to inhibition of established parental adenocarcinomas, as well as an antigenically unrelated fibrosarcoma. The ensuing systemic immunity selectively inhibits subsequent parental cell challenges and cures established parental adenocarcinomas and their lung metastases, although less effectively as the neoplastic mass increases. Multiple injections of interleukin 2-gene-transfected tumor cells may thus be considered a new form of vaccination in the management of minimal residual disease and incipient metastases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221636

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 2.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 3.  Gene therapy for cancer, the course ahead.

Authors:  R G Vile
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.

Authors:  S M Todryk; L J Birchall; R Erlich; N Halanek; J K Orleans-Lindsay; A G Dalgleish
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

5.  Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine.

Authors:  Terry Lichtor; Roberta P Glick; Insug O-Sullivan; Edward P Cohen
Journal:  Curr Genomics       Date:  2006-06       Impact factor: 2.236

6.  Anti-tumor effects and tumor immunogenicity following IL2 or IL4 cytokine gene transfection of three mouse mammary tumors.

Authors:  Y L Matory; M Chen; P S Goedegebuure; T J Eberlein
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

7.  Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.

Authors:  Theresa L Whiteside; Andrea Gambotto; Andreas Albers; Joanna Stanson; Edward P Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-21       Impact factor: 11.205

8.  Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.

Authors:  H Kusnierczyk; E Pajtasz-Piasecka; C Radzikowski
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.738

9.  T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice.

Authors:  T Schüler; Z Qin; S Ibe; N Noben-Trauth; T Blankenstein
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

10.  Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival.

Authors:  Sergiy V Kushchayev; Tejas Sankar; Laura L Eggink; Yevgeniya S Kushchayeva; Philip C Wiener; J Kenneth Hoober; Jennifer Eschbacher; Ruolan Liu; Fu-Dong Shi; Mohammed G Abdelwahab; Adrienne C Scheck; Mark C Preul
Journal:  Cancer Manag Res       Date:  2012-09-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.